This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) concluded the recent trading session at $132.76, signifying a +1.09% move from its prior day's close.
Wall Street Analysts See Abbott (ABT) as a Buy: Should You Invest?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Abbott (ABT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
by Zacks Equity Research
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) concluded the recent trading session at $129.36, signifying a -1.96% move from its prior day's close.
NVST vs. ABT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVST vs. ABT: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Broadcom, T-Mobile, Abbott Laboratories, CBL & Associates Properties and Crown Crafts
by Zacks Equity Research
Zacks Analyst Blog spotlights Broadcom, T-Mobile, Abbott, CBL & Associates, and Crown Crafts with updates on growth, risks, and outlooks.
Top Research Reports for Broadcom, T-Mobile & Abbott
by Mark Vickery
Broadcom, T-Mobile, and Abbott lead Zacks Research Daily with AI gains, 5G leadership, and strong medical device pipelines driving momentum.
MDT Stock May Benefit From New Regulatory Wins for Its MiniMed 780G
by Zacks Equity Research
Medtronic secures FDA milestones for its MiniMed 780G system, expanding use to type 2 diabetes and enabling sensor integration.
Hologic's Panther Fusion Signals More Molecular Diagnostics Upside
by Moumi Mondal
HOLX's Panther Fusion expands its diagnostics menu, fueling assay growth and unlocking more upside in molecular testing.
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
by Zacks Equity Research
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Investing in the Age of Longevity: Silver Economy Stocks in Focus
by Urmimala Biswas
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
ABT Stock Gains From Navitor's Expanded Indication Approval in Europe
by Zacks Equity Research
Abbott wins CE Mark in Europe for expanded Navitor use, boosting its Structural Heart business and lifting ABT stock.
ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?
by Sridatri Sarkar
As the structural heart market expands, Abbott and Edwards battle for leadership. Which stock holds stronger growth momentum now?
What's Driving Abbott's Gross Margin Growth Amid Macro Issues
by Sridatri Sarkar
ABT's gross margin hits 56.4% in Q2, fueled by Medical Devices growth, Nutrition strength, FX tailwinds and cost discipline.
NVST or ABT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVST vs. ABT: Which Stock Is the Better Value Option?
Boston Scientific (BSX) Down 0.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights Amazon.com, Salesforce, Abbott Laboratories and Fossil Group
by Zacks Equity Research
Amazon, Salesforce, Abbott and Fossil Group show diverging trends as AI spending weighs on margins, healthcare pipelines expand, and retail turnarounds gain traction.
Top Research Reports for Amazon.com, Salesforce & Abbott
by Mark Vickery
Amazon posts strong Q2 gains across AWS, Prime and ads, but weak Q3 income guidance and AI costs drag shares lower.
GEHC Positioned for Growth With AI, Global Expansion and Margins
by Zacks Equity Research
GE HealthCare's Q2 results highlight revenue growth, AI-driven innovation, and global expansion with margin gains and strong demand.
DexCom Expands Access and Innovation While Balancing Headwinds
by Zacks Equity Research
DXCM grows on type 2 access, Stelo adoption, and new sensor launches, but faces margin pressures, competition and leadership transition.
Should You Invest in Abbott (ABT) Based on Bullish Wall Street Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Abbott Gains in Nutrition With Adult Segment Leading Growth
by Sridatri Sarkar
ABT Nutrition unit posts steady gains as adult-focused brands like Ensure and Glucerna drive global demand and market share growth.
Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data
by Zacks Equity Research
TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.
Abbott Taps Growing TMVR Market With Tendyne System
by Sridatri Sarkar
ABT wins FDA nod for its Tendyne TMVR system, offering a minimally invasive option for patients with severe mitral valve disease.